Rimonci Capital
VC Fund
Beijing, China
Rimonci Capital is a VC fund in Beijing focused on Health Care and Medical Device. A dedicated to China-Israel cross border investment.
- Total investments:
- 10
- Last investment:
- Lead investor:
- 40%
Last updated:
For AI agents: llms.txt
Industries Rimonci Capital invests in
Stages Rimonci Capital invests in
Countries Rimonci Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $3.6M–$3.6M
- Series A
- $6.6M–$11M
Investment Focus
Industry
- Health Care 5 (50%)
- Medical Device 5 (50%)
- Eyewear 2 (20%)
- Medical 2 (20%)
- Artificial Intelligence 2 (20%)
Stage
- Series A 5 (50%)
- Seed 1 (10%)
- Series B 1 (10%)
- Series C 1 (10%)
- Venture - Series Unknown 1 (10%)
Country
- Israel 5 (50%)
- France 1 (10%)
- United States 1 (10%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Richel Liu
Founder and CEO
|
Founder and CEO | Total investments: 6 | Find email | |
Eddie Wang
COO and Co-Founder
|
COO and Co-Founder | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| TECLens is creating a crosslinking technology that may accurately fix vision issues in healthy eyes as well as treat keratoconus. It provides patients with presbyopia with the ability to regain their ability to read at a distance, controls children's progressive myopia, corrects adult vision problems like hyperopia and low-order myopia, andmore. | $9.3M / Series A / Feb 11, 2025 | ||
| Laclarée develops a pair of adaptive eyeglasses for presbyopia. Its patented technology allows the eyeglasses to adapt in real-time to the scene viewed by the wearer. This major innovation will help milllions of people 45+ years, who are not satisfied with current solutions (progressive lenses, multiple pairs, etc...). | $3.6M / Seed / Jan 28, 2025 | ||
| EyeYon Medical is an Israeli start-up company that develops innovative medical devices for the treatment of corneal edema.EyeYon Medical was founded by Dr. Daphna Ofer, a senior ophthalmologist, Dr. Arie Marcovich, a senior cornea surgeon, and Nahum Ferera, an experienced business executive. The company operates within the Van Leer TechnologyIncubator. | $25M / Series C / Mar 15, 2021 | ||
| EyeControl is a pioneer of medical technology, specializing in innovative communication solutions that address unmet healthcare needs. We implement disruptive AI technologies that connect people and bridge information barriers, facilitating better medical care and decision-making. | $7.5M / Series A / Aug 12, 2020 | ||
| BELKIN Vision develops a laser device to assist healthcare professionals in treating glaucoma. It offers non-invasive, non-contact, instantaneous, painless, and automated devices offering laser therapy and is aimed at promoting accessibility to first-line drop-less glaucoma care by allowing any ophthalmologist to treat patients. | $12.3M / Series B / Jul 21, 2020 | ||
| NovaSight brings pediatric vision care into the digital age. Our integrated eye-tracking AI based solutions for accurate vision assessment and efficient treatment are specifically designed for the unique needs and attention span of children.NovaSight’s management and scientific advisory board is comprised of experienced executives, researchersand key opinion leaders in the field of pediatric vision care. | $8M / Series A / Jul 13, 2020 | ||
| 6over6 offers a digital healthcare platform that enables users to perform their own eye vision test. They have reimagined all fundamental optometric tools and fitted them into smartphone, enabling a complete and accurate measurement of the refractive error of the eye, for eyeglasses and contact lens prescription, using software.GlassesOn isregistered as a Class 1 Exempt Medical Device on the FDA Medical Device Listings. However, GlassesOn does not provide medical advice, and does not replace a full eye health exam. | $11M / Series A / Nov 11, 2017 | ||
| BELKIN Vision develops a laser device to assist healthcare professionals in treating glaucoma. It offers non-invasive, non-contact, instantaneous, painless, and automated devices offering laser therapy and is aimed at promoting accessibility to first-line drop-less glaucoma care by allowing any ophthalmologist to treat patients. | $6.6M / Series A / Jun 05, 2017 | ||
| EyeYon Medical is an Israeli start-up company that develops innovative medical devices for the treatment of corneal edema.EyeYon Medical was founded by Dr. Daphna Ofer, a senior ophthalmologist, Dr. Arie Marcovich, a senior cornea surgeon, and Nahum Ferera, an experienced business executive. The company operates within the Van Leer TechnologyIncubator. | $6.5M / Venture - Series Unknown / Mar 21, 2017 | ||
| See all 10 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Rimonci Capital invest in?
Rimonci Capital invests primarily in Health Care, Medical Device and Eyewear startups, most often at Series A and Seed stage. Most of the 10 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Rimonci Capital's check size?
Rimonci Capital typically joins rounds of $3.6M–$3.6M at Seed and $6.6M–$11M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Rimonci Capital participates in.
How do I contact Rimonci Capital?
Public channels for Rimonci Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Rimonci Capital?
The team at Rimonci Capital includes Richel Liu (Founder and CEO) and Eddie Wang (COO and Co-Founder). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
